Cite
HARVARD Citation
Jenkins, K. et al. (n.d.). 587 Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models. Journal for immunotherapy of cancer. p. A351. [Online].